 - Histologically- or cytologically-proven adenocarcinoma of the breast that is HER2 negative. Subjects with hormone receptor positive or negative status are eligible. Additionally, subjects with triple negative status meaning estrogen receptor negative, progesterone receptor negative and HER2 negative are eligible 